Post-earnings recap
Reported
Tue, Aug 4, 2026
EPS actual
$-0.22
EPS est.
$-0.09
EPS surprise
-158.82%
1-day move
-2.80%
ImmunityBio reported a loss per share of $0.22, missing expectations significantly. The stock reacted negatively, declining by 2.80%. The lack of revenue data and management commentary leaves investors with limited insights into the company's current performance and future outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.22 | N/A | -158.82% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.
ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapies to treat cancer and infectious diseases. As part of the health care sector, its innovations could significantly impact patient outcomes and the future of treatment options.
Last quarter
In Q1-2026, ImmunityBio reported an EPS of -$0.62, missing expectations significantly. The stock reacted negatively, dropping 7.40% the following day.
EPS beat streak
0Q
EPS beat rate
50%
Avg EPS surprise
-90.29%
Avg 1-day reaction
-0.30%
Investors are cautious ahead of the earnings report, especially after a significant miss last quarter. The lack of analyst estimates adds uncertainty to expectations.
Bull case
If ImmunityBio can show improved EPS and revenue growth, it could signal a turnaround, boosting investor confidence and stock price.
Bear case
Continued losses and lack of revenue could lead to further declines in stock price, especially if the company fails to provide clear guidance.
The print will turn on these.
Q1
What is the expected EPS for Q2-2026, and how does it compare to previous quarters?
The market will closely scrutinize EPS to gauge the company's financial health and ability to meet or exceed expectations.
Q2
What are the revenue figures for the quarter, and are there any updates on product pipeline progress?
Revenue performance and updates on the product pipeline are critical for assessing the company's growth trajectory and market position.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The market may be underestimating the potential for ImmunityBio to show improved performance this quarter, especially given recent advancements in their product pipeline.
Supporting evidence
The company has a history of surprising the market positively despite recent misses.
Options pricing suggests a significant move, indicating investor uncertainty that could lead to a larger reaction than expected.
Key risk
If the EPS comes in better than -$0.50, it could shift sentiment dramatically.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around whether ImmunityBio can demonstrate a path to profitability and growth amidst previous losses.
Bull confirmed if
A positive EPS of -$0.50 or better would confirm the bull case, indicating improved financial performance.
Bear confirmed if
An EPS worse than -$0.70 would confirm the bear case, suggesting ongoing financial struggles.
What the market is pricing for the move.
Implied Move
±7.94%
Historical Avg
±7.9%
The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.
Options are pricing ±7.9% while IBRX has averaged ±7.9% over the last 8 prints — setup is roughly in line with history.
ATM IV
1.0%
30d HV
77.0%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing in-line setup in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$1.1M
106,056 sh
2 insiders
Net
$1.1M
Net selling
Most Active Insiders· 2 open-market trades
Likely market behavior by outcome. Not investment advice.
Beat & raise
If ImmunityBio beats expectations, history suggests the stock could rise by around 3.1% on the first day, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may remain stable, but cautious commentary could lead to a muted reaction.
Miss
If the company misses expectations again, history suggests a potential drop of around 1.32%, reflecting ongoing investor concerns.
The lines on the call that would change the story.
$851,088.00
Net selling
$268,760.00
Net selling
Recent Transactions
Oct 2, 2026 · @ $10.50
81,056 sh
$851,088.00
Oct 5, 2026 · @ $10.75
25,000 sh
$268,760.00
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.